Every year more than half a million women lose their lives because of complications of pregnancy and childbirth. Postpartum hemorrhage is the leading cause of death especially in developing countries. Strategies have been developed to prevent and treat postpartum hemorrhage. One of these is the use of uterotonic drugs to prevent and treat atonic postpartum hemorrhage. Misoprostol (prostaglandin E1 analogue) has been emerged as an uterotonic drug with special advantages; being heat stable, can be used orally and rather cheap. So, it can be considered as a potential "Magic Bullet" in the management of postpartum hemorrhage. Because of this potentiality, World Health Organization has been conducting big multicentre randomized clinical trials to evaluate efficacy and safety of misoprostol in the prevention and treatment of postpartum hemorrhage. The findings and implications of these trials will be presented and discussed.

Username
Password